Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Trintellix
Published 2026-02-15 · Last reviewed 2026-02-22 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Vortioxetine (Trintellix) is a multimodal antidepressant approved for adult major depressive disorder; guidelines highlight it as a later-line option when first-line SSRIs/SNRIs are ineffective or poorly tolerated, and when cognitive symptoms persist.[label_vortioxetine][apa_mdd_2023][canmat_mdd_2024]
Weight-neutral metabolism and a relatively low interaction burden make vortioxetine attractive for patients already receiving antipsychotics or mood stabilizers, although cost remains a barrier because only authorized generics are available.
The compare view and the vortioxetine evidence feed can help compare vortioxetine with other pro-cognitive antidepressants when reassessing residual cognitive symptoms or augmentation plans.
Consider when executive dysfunction or residual cognitive complaints remain problematic; provide nausea mitigation strategies during initiation.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Combines serotonin transporter inhibition with serotonergic receptor modulation: 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT3/5-HT7/5-HT1D antagonism to influence downstream neurotransmitters including dopamine, norepinephrine, acetylcholine, and glutamate.[katona2018]
Vortioxetine’s main tolerability limiter is nausea; most other monitoring is SSRI-class safety (suicidality early, hyponatremia risk, serotonergic interaction checks).